Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cord blood transfusions show promise for tiniest babies

NCT ID NCT05612919

Disease control Sponsor: Hospital Clinic of Barcelona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether red blood cells from umbilical cord blood are safe and work as well as standard adult donor blood for transfusions in extremely preterm infants (born before 28 weeks). 41 babies received small transfusions, and researchers monitored their vital signs, oxygen levels, and overall health. The goal is to see if cord blood is a reliable alternative for these vulnerable newborns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
red blood cells from umbilical cord blood
What this could lead to
If successful, this could provide a new, safe source of red blood cells for transfusions in extremely premature babies, potentially reducing complications.
What could go wrong
This is a small, early-stage study with only 41 participants, so results may not apply broadly. The product is still under development, and safety monitoring is ongoing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

41 people

The number who actually took part.

Started

Sep 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 12 weeks

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent from parents or legal guardians * Preterm infants born earlier than 28 weeks of gestational age. * Admission to the neonatal intensive care unit of the participating hospital (Hospital Clínic of Barcelona) Exclusion Criteria: * Previous transfusion * Isoimmunization * Hydrops fetalis * Major congenital malformations * Congenital infections * Hemoglobinopathies * Extreme urgency of blood availability (hypovolemic shock, disseminated intravascular coagulopathy...) * Be part of another clinical trial that may interfere with the results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia of prematurity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia anemia of prematurity beta thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Erythrocyte transfusion Infant, extremely premature Umbilical cord issue

Contacts and locations

Locations

  • Hospital Clinic of Barcelona

    Barcelona, Barcelona, 08028, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.